AI Engines For more Details: Perplexity Kagi Labs You
Allergic Rhinitis: Carbinoxamine maleate helps relieve symptoms associated with allergic rhinitis, including sneezing, runny or stuffy nose, itching, and nasal congestion. It blocks the action of histamine, a chemical released during allergic reactions that causes inflammation and symptoms.
Allergic Conjunctivitis: Carbinoxamine maleate may be used to alleviate symptoms of allergic conjunctivitis, such as redness, itching, and watery eyes. It helps reduce inflammation and irritation in the eyes caused by allergic reactions.
Urticaria (Hives): Carbinoxamine maleate can be effective in treating acute episodes of hives (urticaria) by reducing itching and skin rash associated with allergic reactions.
Pruritus (Itching): It may also be prescribed for the symptomatic relief of itching associated with allergic skin conditions, such as atopic dermatitis (eczema) or contact dermatitis.
Motion Sickness: Carbinoxamine maleate has anticholinergic properties, which can help alleviate symptoms of motion sickness, including nausea and vomiting. It is sometimes used in combination with other medications for motion sickness relief.
Common Cold: Carbinoxamine maleate may be included in some over-the-counter cough and cold medications to relieve symptoms such as sneezing, runny nose, and nasal congestion. However, its efficacy for this purpose is limited, and it is not recommended for children under certain ages due to safety concerns.
Antiemetic: In addition to its antihistamine properties, carbinoxamine maleate has mild antiemetic (anti-nausea) effects, which may be beneficial for individuals experiencing nausea or vomiting due to motion sickness or other causes.
Side Effects: Common side effects of carbinoxamine maleate may include drowsiness, dizziness, dry mouth, blurred vision, constipation, and urinary retention. These side effects are more common with higher doses and may be more pronounced in elderly individuals.
Sedative Effects: Carbinoxamine maleate can cause sedation and impair cognitive and motor function, especially when taken in higher doses or in combination with other medications that have sedative effects. Patients should avoid activities requiring mental alertness, such as driving or operating machinery, until they know how the medication affects them.
Caution: Carbinoxamine maleate should be used with caution in certain populations, including elderly individuals, children, pregnant women, and individuals with certain medical conditions (such as glaucoma, urinary retention, or prostate enlargement). It is important to consult a healthcare professional before using carbinoxamine maleate, especially in these populations.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.3 | 0.3 | |
| Allergies | 0.3 | 0.3 | 0 |
| Alzheimer's disease | 0.3 | 0.6 | -1 |
| Ankylosing spondylitis | 0.1 | 0.3 | -2 |
| Asthma | 0.3 | 0.3 | |
| Atherosclerosis | 0.3 | 0.3 | |
| Atrial fibrillation | 0.1 | -0.1 | |
| Autism | 1.2 | 0.5 | 1.4 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| Biofilm | 0 | 0 | |
| Breast Cancer | 0 | 0 | |
| Cancer (General) | 0.3 | 0.1 | 2 |
| Carcinoma | 0.3 | 0.3 | |
| Celiac Disease | 0.1 | 0.1 | |
| Chronic Fatigue Syndrome | 0.3 | 0.1 | 2 |
| Chronic Kidney Disease | 0.6 | 0.6 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.3 | 0 |
| Chronic Urticaria (Hives) | 0.1 | -0.1 | |
| Colorectal Cancer | 1 | 0.3 | 2.33 |
| Constipation | 0.1 | 0.1 | |
| COVID-19 | 0.7 | 0.5 | 0.4 |
| Crohn's Disease | 0.4 | 0.3 | 0.33 |
| Cushing's Syndrome (hypercortisolism) | 0.1 | -0.1 | |
| deep vein thrombosis | 0 | 0 | |
| Denture Wearers Oral Shifts | 0 | 0 | |
| Depression | 0.7 | 0.1 | 6 |
| Eczema | 0.3 | 0.3 | |
| Eosinophilic Esophagitis | 0.3 | 0.3 | |
| Epilepsy | 0.3 | 0.3 | |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.3 | 0.1 | 2 |
| Functional constipation / chronic idiopathic constipation | 0.1 | 0.7 | -6 |
| gallstone disease (gsd) | 0.3 | -0.3 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 0.4 | |
| Generalized anxiety disorder | 0.3 | 0.3 | |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.9 | 0.6 | 0.5 |
| Heart Failure | 0 | 0 | |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| hypertension (High Blood Pressure | 0.6 | 0.6 | |
| IgA nephropathy (IgAN) | 0.3 | 0.1 | 2 |
| Inflammatory Bowel Disease | 0.7 | 0.3 | 1.33 |
| Intelligence | 0.1 | -0.1 | |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 0.7 | 0.1 | 6 |
| Liver Cirrhosis | 0.3 | 0.3 | 0 |
| Long COVID | 0.7 | 0.3 | 1.33 |
| Mast Cell Issues / mastitis | 0 | 0 | |
| ME/CFS with IBS | 0 | 0 | |
| Metabolic Syndrome | 0.3 | 0.4 | -0.33 |
| Mood Disorders | 0.5 | 0.1 | 4 |
| Multiple Sclerosis | 0.4 | 0.1 | 3 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 0.6 | |
| Obesity | 1 | 0.4 | 1.5 |
| obsessive-compulsive disorder | 0.1 | 0.7 | -6 |
| Osteoarthritis | 0.3 | 0.3 | |
| pancreatic cancer | 0 | 0 | |
| Parkinson's Disease | 0.6 | 0.6 | 0 |
| Polycystic ovary syndrome | 0.4 | 0.4 | |
| primary biliary cholangitis | 0.3 | -0.3 | |
| Primary sclerosing cholangitis | 0.3 | 0.3 | |
| Psoriasis | 0.1 | -0.1 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.1 | 0.3 | -2 |
| Rosacea | 0.6 | 0.6 | |
| Schizophrenia | 0.3 | 0.3 | |
| Sjögren syndrome | 0.1 | 0.1 | |
| Sleep Apnea | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.3 | 0.3 | |
| Systemic Lupus Erythematosus | 0.3 | 0.3 | |
| Tic Disorder | 0.1 | 0.1 | 0 |
| Type 1 Diabetes | 0.1 | 0.1 | 0 |
| Type 2 Diabetes | 0.7 | 0.4 | 0.75 |
| Ulcerative colitis | 0.4 | 0.2 | 1 |
| Unhealthy Ageing | 1.1 | 1.1 |
